Combinations of Bevacizumab with Sunitinib maleate (prescribed for renal and gastrointestinal cancer) may cause severe side effects. Platinum or taxane-based therapies for lung or metastatic breast cancer, in combination with Bevacizumab, may increase the risk of severe side effects.